Desarda Tissue Technique vs Lichtenstein Technique for Primary Inguinal Hernia Repair
Condition(s) studied
Investigational drug(s) / intervention(s)
Desarda: This technique prevent from using a mesh to surgical repair of a inguinal hernia
Lichtenstein: This technique implies using a mesh to surgical repair of a inguinal hernia
Study summary
This study aims to evaluate whether a surgical technique (Desarda) is superior to the commonly used surgical technique (Lichtenstein) in inguinal hernia repair concerning the occurrence of postoperative complications. The Lichtenstein technique involves the use of a mesh, while the Desarda technique does not.
Eligibility
Primary outcome measure(s)
- Rate of Participants with Post-surgery Complications — 3 months
Any of the following complications: ● Sensation of a foreign body that persists beyond 3 months after surgery, self-reported by the participant ● Seroma within the first 30 days after surgery, verified through physical examination by a surgeon ● Hematoma within the first 30 days after surgery, verified through physical examination by a surgeon ● Infection at the surgical site within the first 30 days after surgery, verified by a surgeon ● Severe postoperative pain (7 or higher on the visual analog scale \[VAS\]) within the first 30 days after surgery, self-reported by the participant ● Chronic postoperative pain (persisting more than three months after surgery), self-reported by the participant ● Persistent loss of skin sensitivity beyond 30 days after surgery, self-reported by the participant ● Limitation of normal activities at home, outside the home, or at work beyond 3 months after surgery, self-reported by the participant
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| CSAPG | Sant Pere de Ribes | Barcelona | Recruiting |
More Consorci Sanitari de l'Alt Penedès i Garraf trials in Spain
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06650878 on ClinicalTrials.gov ↗ ← All trials in Spain